RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw

RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw.

Affiliations of authors: Oncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy (VF, GN); Department of Surgical, Oncology and Oral Sciences, Sector of Oral Medicine, Palermo University, Palermo, Italy (GC); University of Tennessee Health Science Center, College of Dentistry, Memphis, TN (CM); DH Oncology, Universit a Campus Bio-Medico, Rome, Italy (DS); Department of N...

[Osteonecrosis of the jaw].

The paper concerns osteonecrosis of the jaw (ONJ). It is a rare but serious clinical condition. It can develop in patients treated in oncologic doses with bisphosphonates but also with denosumab. In osteoporosis ONJ seems to be very rare. Definition, pathogenesis, risk factors, prevention and treatment, and the frequency of ONJ are presented.

Animal models of osteonecrosis of the jaw.

Bevacizumab-associated osteonecrosis of the jaw.

Medication-Related Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is a common side effect of antiresorptive drugs that are administered to cancer patients for bone metastasis, multiple myeloma, and osteoporosis. Since both bisphosphonate (BP) and denosumab show anti-bone resorption effects with ONJ, antiresorptive agent-related ONJ (ARONJ) has been suggested as a comprehensive term encompassing both BP-related osteonecrosis of t...